On October 19, 2026, Silence Therapeutics announced a definitive agreement under which Germany's Merck KGaA plans to acquire the clinical-stage biotechnology company for cash. The headline valuation is approximately $1.3 billion of equity, with $20 payable per American depositary share (ADS). The proposed price represents a 130% premium to Silence's closing ADS price on Friday, October 16. For investors, the important distinction is between the value promised by a signed transaction and the value already delivered by a completed one.
This analysis is based on the company's announcement filed with the U.S. Securities and Exchange Commission and information available through 8:00 p.m. Eastern Time on October 19. Silence trades on Nasdaq under SLN, while the acquirer is Merck KGaA of Darmstadt, Germany, which is distinct from the U.S. pharmaceutical company Merck & Co. The deal was announced Monday. It had not closed by the cutoff, and the expected completion period lies in the first quarter of 2027.
Deal terms: $1.3 billion equity value is not $1.1 billion enterprise value
Silence's SEC-filed announcement gives an approximately $1.3 billion equity valuation and an approximately $1.1 billion enterprise valuation. The difference reflects valuation definitions that consider items such as net cash and debt rather than two competing estimates of the purchase price. The equity value is the relevant broad headline for shareholders; enterprise value is frequently more useful when comparing the value paid for operating assets across companies with different balance sheets.
Each Silence ADS represents three ordinary shares. The agreement therefore specifies $20 per ADS, equivalent to approximately $6.6667 for each ordinary share. The announcement also calculates an 82% premium to the 30-day volume-weighted average ADS price of $10.99. The 130% figure instead compares the offer with the October 16 closing ADS price. Those percentages use different denominators and both can be correct. Neither is a promised return to someone buying SLN after the announcement.
The proposed transaction is structured as a U.K. scheme of arrangement under the Companies Act 2006. Silence shareholders must approve it, the High Court of Justice of England and Wales must sanction it, and applicable regulatory approvals and other customary conditions must be satisfied. The Silence board unanimously approved the deal. Certain holders representing roughly 14% of voting power signed support agreements. That support is meaningful, but it does not by itself constitute the required overall shareholder approval or court sanction.
Why Merck wants a company without an approved commercial product
Silence develops medicines built around short interfering RNA, or siRNA. Rather than supplying a missing protein, a successful siRNA therapy can reduce expression of a selected gene involved in disease biology. This mechanism has attracted industry interest because the biological target can sometimes be approached upstream of disease symptoms. The clinical and commercial risks remain substantial, particularly when a program is moving toward large confirmatory studies.
Silence's lead asset, divesiran, targets TMPRSS6 in the liver. The intended effect is to increase hepcidin, change iron handling and restrict the iron available for excessive red-blood-cell production. The target disease, polycythemia vera, is a blood cancer characterized by excess red cells and an elevated risk of clotting and other complications. Maintaining hematocrit below 45% is an important treatment objective. Existing care can involve repeated therapeutic phlebotomy and other interventions; an effective targeted option could change the treatment burden for some patients.
Divesiran has U.S. Food and Drug Administration Fast Track and Orphan Drug designations for polycythemia vera. Those designations can provide development-related benefits and reflect the regulatory framework for serious or rare conditions. They are not marketing approval, a successful Phase 3 trial, or a guarantee of future revenue. The companies highlighted Phase 2 progress, but later-stage efficacy, safety, manufacturing and regulatory review still stand between an experimental medicine and a marketed treatment.
What the premium says, and what it does not
A premium of 130% over the preceding closing price indicates the buyer valued the platform, pipeline and strategic fit substantially above the market's last unaffected quotation. That may reflect expected research synergies, competitive bidding or different views of long-run commercial potential. It does not establish that the standalone biotechnology business was worth exactly $20 per ADS before the deal, or that all developers using siRNA deserve an equivalent takeover multiple.
Biotechnology takeovers often price an asymmetric set of outcomes. A candidate that succeeds clinically may address a valuable specialized market, but failure in a pivotal trial can eliminate much of the anticipated franchise value. A large buyer can diversify this risk across a wider portfolio, while a smaller independent developer may face significant dilution if it needs new equity financing. These differences help explain why acquisition value can exceed what public investors had previously assigned to the standalone company.
Trading consequences and the merger-spread debate
When a cash acquisition is announced, a target's share price often moves toward, but not necessarily all the way to, the agreed consideration. Any discount can reflect the expected time until payment, the probability of transaction failure and a required risk premium. A target trading below the offer price is not automatically a low-risk arbitrage opportunity. If shareholder approval, court approval or regulation prevents completion, the shares could trade on the value of the independent pipeline rather than near the offer.
The competing bullish argument is that a unanimously backed definitive agreement and visible strategic rationale can reduce deal uncertainty. The skeptical argument is that closing conditions, possible litigation and clinical-program uncertainty still matter. The transaction is all cash, so there is no direct exchange ratio tied to Merck KGaA's stock price, but the purchaser's ability and willingness to complete the transaction remain part of closing risk.
What comes next for SLN holders
The parties expect completion in the first quarter of 2027; an exact closing day, shareholder vote date and court hearing date are not specified in the verified announcement. Silence said it intends to file transaction-related proxy materials with the SEC. Investors should read those materials when available for the detailed agreement, termination provisions and voting timetable rather than relying on initial headlines.
The key risks are delayed or failed approvals, competing bids that complicate timing, unexpected liabilities, litigation and the ultimate clinical performance of divesiran. A risk assessment should distinguish the economics of an announced $20 cash deal from the uncertainty of developing RNA therapeutics independently. October 19 established a signed acquisition and a clear proposed price. The next decisive evidence will be formal transaction filings, shareholder and court milestones, regulatory progress and, eventually, whether the drug pipeline can produce the value the acquirer is seeking.